An external tunneled central venous access device (CVAD) is a small plastic tube that is tunneled under the skin into a major vein for long-term use (Figure 1). Patients who require a tunneled CVAD are some of the sickest patients we encounter and include oncology, hematology, and gastrointestinal (intestinal failure) patients. These patients are heavily reliant on their tunneled CVAD, which can be a lifeline for long-term administration of chemotherapeutics, IV medications, blood product transfusions, antibiotics, enteral nutrition, blood draws and fluids. Unfortunately, nearly 30% of pediatric external tunneled CVADs fail prior to the completion of treatment. External tunneled CVAD failures lead to unnecessary morbidity and mortality, interruption of medical therapy, and the added costs and risks associated with additional procedural complications. It is hypothesized that a newly designed securement method for external tunneled central venous access devices (CVAD) will reduce catheter-related complications and increase patient, parent and provider satisfaction, compared to the current standard of care, which is a clear transparent film dressing over the catheter exit site. A 20 patient, prospective clinical trial is proposed to address the following specific aims, which will determine if the securement device: 1. Is rated by patients, parents and providers as easy to apply and comfortable for users 2. Reduces CVAD-related complications, such as delayed healing of the tract, catheter-related infections, and episodes of catheter dislodgement 3. Improves the quality of life for patients and their parents 4. Is preferred over the standard, clear transparent dressing alone 5. Requires any design modifications to improve performance and/or comfort of the device
A prospective pilot trial to examine the feasibility for a new CVAD securement device prototype (see appendix for computer-aided design drawings). Eligible patients will be identified by either mid-level providers, consulting services, or attending surgeons. Researchers will obtain consent from the patient or their parent/legal guardian. Caregivers will be educated on how to apply the securement device and will be given a number to call should they have any questions or concerns. Once the patient is enrolled and provided with the device, the investigators will perform follow up telephone interviews at one and three weeks to evaluate their experience and ensure they did not experience any adverse events. The investigators will prospectively record the primary and secondary outcomes regarding use of the securement device, including: comfort, quality of materials, adhesive, ease of use, skin problems, infections, dislodgement episodes, catheter breakage, types and numbers of interactions with healthcare providers (phone calls, emergency department and clinic visits), perceived safety, and overall impressions.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Participants will be given a prototype of a CVAD securement device for a three week trial. Descriptive data relating to user satisfaction will be collected at 1 and 3 weeks
Children's Hospital Colorado
Aurora, Colorado, United States
RECRUITINGComfort
Survey question asking for qualitative description of satisfaction
Time frame: 3 weeks
quality of materials
Survey question asking for qualitative description of satisfaction
Time frame: 3 weeks
Quality of Adhesive
Survey question asking for qualitative description of satisfaction
Time frame: 3 weeks
Ease of use
Survey question asking for qualitative description of satisfaction
Time frame: 3 weeks
Skin irritation
Survey question asking for qualitative description of complication, if applicable
Time frame: 3 weeks
Infection
Survey question asking for qualitative description of complication, if applicable
Time frame: 3 weeks
dislodgement
Survey question asking for qualitative description of complication, if applicable
Time frame: 3 weeks
catheter breakage
Survey question asking for qualitative description of complication, if applicable
Time frame: 3 weeks
types and numbers of interactions with healthcare providers
Survey question asking for qualitative description of interaction, if applicable
Time frame: 3 weeks
Perceived safety
Survey question asking for qualitative description of perceived device safety
Time frame: 3 weeks
overall impression
Survey question asking for qualitative description of overall impression of device
Time frame: 3 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.